Actelion Pharmaceuticals

Actelion Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative treatments for rare and serious diseases, especially pulmonary hypertension—a condition that affects blood flow in the lungs and heart. Known for their focus on research and targeted therapies, Actelion aims to improve patient quality of life through specialized medicines. In 2017, it was acquired by Johnson & Johnson, enhancing its resources while continuing to operate with a focus on rare diseases. The company is recognized for its commitment to scientific advancement and addressing unmet medical needs with innovative solutions.